Our Approach

Fix the gastrointestinal microbiome - Introducing NRGBiotic, a probiotic first, clinically trialled to show depression score reduction in 8 weeks.

14 patents, multiple peer-reviewed publications, Phase 2a outcomes showed:

The Primary Outcomes (2/2 MET) were:

1. MET – Participants taking both NRGBiotic™, and an anti-depressant had greater symptom remission over the 8 weeks period than those on an anti-depressant alone (p=0.015).

2. MET - Incidence of dysbiosis assessed by faecal analysis showed both groups were dysbiotic, holding to the premise that anti-depressant medications adversely affect the intestinal bacteria

   leading to an unbalanced dysbiotic gut.

The Secondary Outcomes (2/3 MET) were:

1. MET - Participants taking both NRGBiotic™ and an anti-depressant had greater proportional

   increase in Quality of Life (QoL) Scale from baseline to 8 weeks, than those on anti-depressants

   alone (p=0.015).

2. MET - Participants taking both NRGBiotic™ and an anti-depressant had greater improvement in

   non-clinical levels of symptoms (e.g., interpersonal, social, etc) than those on anti-depressant

   medications alone (p=0.003)

3. NOT MET - The proportion of participants with a reduction in lipopolysaccharides (LPS^) showed no noticeable differences between the groups.

The results are significant supporting Medlab’s proprietary patented product NRGBiotic™ is a vital adjunctive therapy to antidepressant medications - Research shows approximately 33% of patients prescribed an antidepressant medication are non-responders. Medlab conducted this study with Major Depressive Disorder patients, with 33 also being non-responder patients, our results highlight that using NRGBiotic™ with an antidepressant produced significantly better outcomes than taking antidepressant medications with a placebo.